Page last updated: 2024-10-24

vesicle budding from membrane

Definition

Target type: biologicalprocess

The evagination of a membrane, resulting in formation of a vesicle. [GOC:jid, GOC:tb]

Vesicle budding is a fundamental cellular process that involves the formation of small, membrane-bound vesicles from a larger donor membrane. This process is essential for various cellular functions, including protein trafficking, signal transduction, and membrane remodeling. Here's a detailed description of the biological process of vesicle budding:

1. **Initiation:** Vesicle budding starts with the recruitment of specific proteins to the donor membrane, forming a bud initiation site. These proteins include:
* **Coat proteins:** These proteins assemble on the cytosolic surface of the donor membrane, shaping the nascent vesicle and driving its formation. Different types of coat proteins are involved in different vesicle budding pathways, such as clathrin, COPI, and COPII.
* **Adaptor proteins:** These proteins bind to cargo molecules and interact with coat proteins, linking the cargo to the budding vesicle.
* **Small GTPases:** These proteins act as molecular switches, regulating the assembly and disassembly of coat proteins and other components of the budding machinery.

2. **Membrane deformation:** As coat proteins assemble, they begin to curve the membrane, forming a bud. This deformation is driven by several factors:
* **Protein-protein interactions:** Coat proteins interact with each other and with the membrane, leading to membrane curvature.
* **Lipid modifications:** The lipid composition of the donor membrane can influence its curvature. Some lipids promote membrane bending, while others resist it.
* **Mechanical forces:** The cytoskeleton can provide mechanical force to aid in vesicle budding.

3. **Cargo selection:** During budding, specific cargo molecules, such as proteins, lipids, or even other organelles, are selectively packaged into the forming vesicle. This selection is crucial for the accurate delivery of cargo to its destination.

4. **Scission:** Once the bud has reached a certain size and shape, it needs to be pinched off from the donor membrane. This process, known as scission, involves the recruitment of specific proteins that sever the connection between the vesicle and the donor membrane. Several proteins are involved in this step, including:
* **Dynamin:** This protein forms a ring around the neck of the bud, and through GTP hydrolysis, it constricts the neck, ultimately leading to vesicle fission.
* **Other scission proteins:** These proteins work in conjunction with dynamin to facilitate the final separation of the vesicle.

5. **Uncoating:** After scission, the vesicle often sheds its coat proteins, which are then recycled back to the donor membrane for subsequent budding events. This uncoating allows the vesicle to interact with its target membrane and deliver its cargo.

Overall, vesicle budding is a complex and highly regulated process that is critical for maintaining cellular function. This intricate process involves the coordinated action of numerous proteins and lipid modifications to ensure accurate cargo selection, vesicle formation, and efficient delivery of cargo to its final destination.'
"

Proteins (3)

ProteinDefinitionTaxonomy
P2X purinoceptor 7A P2X purinoceptor 7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99572]Homo sapiens (human)
Protein S100-A10A protein S100-A10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P60903]Homo sapiens (human)
Annexin A2An annexin A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07355]Homo sapiens (human)

Compounds (20)

CompoundDefinitionClassesRoles
oxatomideoxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.

oxatomide: structure; an anti-allergic & an anti-asthmatic
benzimidazoles;
diarylmethane;
N-alkylpiperazine
anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde
purinergic receptor P2X antagonist
suraminsuramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.

Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
naphthalenesulfonic acid;
phenylureas;
secondary carboxamide
angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
alpha,beta-methyleneadenosine 5'-triphosphatealpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpdnucleoside triphosphate analogue
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
N-(3,4-dimethylphenyl)-2-[[5-[[(4,6-dimethyl-2-pyrimidinyl)thio]methyl]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]thio]acetamideanilide
8-azidoadenosine 5'-triphosphate
6-thioinosine-5'-triphosphateorganic molecule
mrs2159MRS2159: an antagonist of both P2X1 and P2X7 receptors
imd 0354N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first sourcebenzamides
kn 62KN 62: inhibitor of Ca/calmodulin-dependent protein kinase IIpiperazines
az 11645373AZ 11645373: InChIKey: VQEHBLGYANQWEA-UHFFFAOYSA-N
az10606120AZ10606120: a P2X7 receptor antagonist
ce 224,535CE 224,535: structure in first source
a-438079
af 3535-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine: a P2X3 and P2X2/3 receptor antagonist; structure in first source
gsk1482160
a-839977A-839977: a selective P2X7 receptor antagonist, analgesic; structure in first source
jnj-47965567JNJ-47965567: a P2X7 purinergic receptor antagonist; structure in first source
mk-8742elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.

elbasvir: inhibits NS5A protein of hepatitis C virus
carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly
antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent